- Manufacturer : Mylan Pharmaceuticals Pvt Ltd
- Equivalent Brands : Hepcinat
- Generic Brands : Sofosbuvir / Velpatasvir
Ledipasvir is a potent inhibitor of HCV NS5A, a viral phosphoprotein that plays an important role in viral replication, assembly, and secretion. Sofosbuvir is a nucleotide analog inhibitor of hepatitis C virus NS5B polymerase the key enzyme mediating HCV RNA replication. The triphosphate form of sofosbuvir mimics the natural cellular uridine nucleotide and is incorporated by the HCV RNA polymerase into the elongating RNA primer strand, resulting in viral chain termination.
Ledipasvir inhibits the HCV NS5A protein, which is required for viral replication.
Sofosbuvir inhibits HCV NS5B RNA-dependent RNA polymerase, which is required for viral replication.
Myhep Lvir Tablet helps in the treatment of chronic hepatitis C (HCV). This drug is used in a combination with another drug, to prevent the spread of HCV throughout the body.
MYHEP-LVIR is a combination of two hepatitis C virus (HCV) antiviral drugs in a single form. Each single tablet contains ledipasvir and sofosbuvir.
Patients who have liver issues, or kidney problems and are undergoing dialysis, are not advised the use of Myhep Lvir Tablet. Also inform your doctor about any other health issues you are suffering from and if you are taking any medicines to treat them.
Myhep Lvir Tablet is meant to be taken orally, either with food or without. Antacids containing magnesium or aluminum should not be consumed for a few hours after taking the drug. The drug should be taken regularly, preferably at a particular time each day. Try not to miss any doses.
Myhep Lvir Tablet may result in a few common side effects such as irritation, pain in the muscles, diarrhea, headache, cough, and problems with sleep. Side effects that are less common but may occur none the less are loss of appetite, discontentment, dizziness and problems with concentration. If these side effects persist or deteriorate, get in touch with your health care provider immediately.
In case of adults, 1 tablet is prescribed to be taken every day for about 12 weeks.
In addition to its intended effect, Myhep Lvir Tablet may cause some unwanted effects too. In such cases, you must seek medical attention immediately. This is not an exhaustive list of side effects. Please inform your doctor if you experience any adverse reaction to the medication.
MyHep LVIR is not always suitable for all patients. Do not take MyHep LVIR as it is contradicted in the following known cases:
Pregnancy / Breast Feeding – Do not use this medicine if you are pregnant or breastfeeding or trying to get pregnant.
Unprotected Sex – This medicine is contradicted for use during unprotected s**ual intercourse as it may also lead to birth defects.
Antacids – It is recommended not to intake this medicine within a before and after 4 hour period of taking any Antacids.
Ledipasvir / Sofosbuvir Medications – Do not take MyHep LVIR when taking other medications having Ledipasvir and/or Sofosbuvir as their active ingredients. MyHep LVIR is also contradicted when taken alongside other medications used in the treatment of Chronic Hepatitis C Virus (CHC) infection.
Ledipasvir / Sofosbuvir Allergy – MyHep LVIR is contradicted for use, if you are allergic to Ledipasvir and/or Sofosbuvir which are the active ingredients of MyHep LVIR.
Other Herbal / Dietary Supplements / Prescription Medicines / OTC Medicines – MyHep LVIR may be contradicted for use when taken with other medications to treat Tuberculosis, Seizures, HIV, Cancer, Cholesterol, Heart ailments and other anti-viral medications. Consult your medical doctor before using MyHep LVIR by providing a list of any and all existing medications that you are taking to ascertain the safety and use of MyHep LVIR
Serious symptomatic bradycardia may occur in patients taking amiodarone and sofosbuvir in combination with another direct acting antiviral (daa), particularly in patients also receiving beta blockers, or those with underlying cardiac comorbidities and/or advanced liver disease. Coadministration of amiodarone with sofosbuvir in combination with another daa is not recommended.
Ribavirin may cause birth defects and fetal death and animal studies have shown interferons have abortifacient effects; avoid pregnancy in female patients and female partners of male patients. Patients must have a negative pregnancy test prior to initiating therapy.
MyHep LVIR is to be administered under the strict supervision of a Hepatologist only. An extra patient leaflet is available with ledipasvir and sofosbuvir. Talk to your pharmacist if you have questions about this information.
Important – The correct dosage and prescription commonly depend on the patient and the condition being treated. Duration of dosage can range between 8 weeks to 24 weeks and the correct duration of treatment is to be determined by your medical practitioner or doctor as it will depend on the patient’s condition and their response to the therapy. Do not adjust your dosage without the approval of your medical practitioner or doctor. This product is only for use as prescribed and instructed by a doctor or medical practitioner.
MYHEP-LVIR is a combination of ledipasvir and sofosbuvir and is used to treat chronic (long-lasting) hepatitis C, a viral infection of the liver. It may sometimes be used with another antiviral medication (ribavirin). These drugs work by reducing the amount of hepatitis C virus in your body, which helps your immune system fight the infection and may help your liver recover.
Store MyHep LVIR at room temperature below 86° F (30° C).
Keep MyHep LVIR in its original container.
Do not use MyHep LVIR if the seal over the bottle opening is broken or missing.
Keep MyHep LVIR and all medicines out of the reach of children.